SYRE - Spyre Therapeutics, Inc.

QQQ $ 617.50 $ 6.52 (1.07 %)

DIA $ 472.45 $ 4.92 (1.05 %)

SPY $ 677.25 $ 5.49 (0.82 %)

TLT $ 91.47 $ 0.04 (0.04 %)

GLD $ 378.59 $ -1.27 (-0.34 %)

Previous Close

$ 23.37

Open

$ 22.56

Bid

$ 21.01 x 26,830

Ask

$ 25.00 x 104

Day's Range

$ 22.35 - $ 23.59

52 Week Range

$ 10.91 - $ 40.26

Volume

700,704

Average Volume

Market Cap

1.41B

Beta (5Y Monthly)

$ 1.27

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-05-2025	06-30-2025	10-Q
2	05-08-2025	03-31-2025	10-Q
3	02-27-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-07-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	02-29-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q
9	08-11-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-02-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-05-2022	03-31-2022	10-Q
15	03-08-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-05-2021	06-30-2021	10-Q
18	05-10-2021	03-31-2021	10-Q
19	03-18-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	02-24-2020	12-31-2019	10-K
24	11-06-2019	09-30-2019	10-Q
25	08-06-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	03-07-2019	12-31-2018	10-K
28	11-08-2018	09-30-2018	10-Q
29	08-09-2018	06-30-2018	10-Q
30	05-08-2018	03-31-2018	10-Q
31	03-13-2018	12-31-2017	10-K
32	11-07-2017	09-30-2017	10-Q
33	08-09-2017	06-30-2017	10-Q
34	05-09-2017	03-31-2017	10-Q
35	03-23-2017	12-31-2016	10-K
36	11-09-2016	09-30-2016	10-Q
37	08-09-2016	06-30-2016	10-Q
38	05-19-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Spyre Therapeutics Releases New Data From ...
10/24/2025 12:04:25

Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody c...

dominos-pizza-posts-upbeat-results-joins-astria-therapeutics-albertsons-companies-polaris-and-other-big-stocks-moving-higher-on-tuesday

Domino's Pizza Posts Upbeat Results, Joins...
10/14/2025 14:15:51

Reported Earlier, Spyre Therapeutics Price...
10/14/2025 04:59:41

Spyre Therapeutics Reveals Proposed Public...
10/13/2025 20:03:00

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:S...

12 Health Care Stocks Moving In Friday's A...
10/10/2025 21:06:24

Reported Sunday, Spyre Therapeutics Unveil...
10/06/2025 06:33:36

this-united-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday

This United Therapeutics Analyst Begins Co...
09/26/2025 12:03:22

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Deutsche Bank Initiates Coverage On Spyre ...
09/26/2025 11:38:09

Deutsche Bank analyst David Hoang initiates coverage on Spyre Therapeutics (NASDAQ: SYRE) with a Buy rating and announces Pr...

BTIG Reiterates Buy on Spyre Therapeutics,...
09/16/2025 10:43:02

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $70 price target.

Spyre Therapeutics Doses First Patient In ...
09/15/2025 12:02:29

Spyre Therapeutics, Inc.

Spyre Therapeutics Q2 EPS $(0.49) Beats $(...
08/05/2025 20:39:34

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(...

Spyre Therapeutics Announces Interim Phase...
06/17/2025 11:32:35

Spyre Therapeutics To Announce Interim Pha...
06/16/2025 20:10:49

Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, do...

Spyre Therapeutics Q1 EPS $(0.62) Beats $(...
05/08/2025 21:16:51

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(...

This Weyerhaeuser Analyst Begins Coverage ...
04/08/2025 12:53:59

Leerink Partners Initiates Coverage On Spy...
04/08/2025 11:56:32

Leerink Partners analyst Faisal Khurshid initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Outperform rating and...

Spyre Therapeutics Announces First Partici...
03/27/2025 20:11:42

Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opport...

Spyre Therapeutics Q4 2024 GAAP EPS $(0.81...
02/27/2025 21:41:09

Spyre Files For $500 Mixed Shelf Offering
02/27/2025 21:39:21

-SEC Filing

Spyre Therapeutics Anticipates Cash Runway...
01/13/2025 13:23:20